Related Experiment Video

Updated: Jun 15, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

N-3 polyunsaturated fatty acids in heart failure: mechanisms and recent clinical evidence

R Marchioli1, M G Silletta, G Levantesi

  • 1Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy. marchioli@negrisud.it

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|March 4, 2010
PubMed

Insights

Omega-3 fatty acids (n-3 PUFA) significantly reduced mortality and hospital admissions in chronic heart failure patients. This promising treatment offers improved survival for heart failure (HF) patients already on standard therapies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nutritional Science

Background:

  • Heart failure (HF) remains a significant health burden despite advances in treatment.
  • Improved therapeutic strategies are needed to reduce mortality, enhance quality of life, and lower hospitalization costs in HF patients.

Purpose of the Study:

  • To present the results of the GISSI-HF study on n-3 PUFA in heart failure patients.
  • To review existing clinical evidence regarding n-3 PUFA and heart failure risk.
  • To discuss the potential mechanisms of n-3 PUFA's clinical benefits in HF.

Main Methods:

  • The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure (GISSI-HF) trial.
  • A large-scale, randomized, double-blind, placebo-controlled study.
  • Involved patients with chronic heart failure receiving standard therapies.

Main Results:

  • Daily intake of n-3 PUFA (850-882 mg/d) reduced all-cause mortality.
  • n-3 PUFA supplementation decreased hospital admissions for cardiovascular reasons.
  • Clinical benefits may be linked to antiarrhythmic effects and potentially HF progression mechanisms.

Conclusions:

  • n-3 PUFA supplementation is a promising therapeutic option for improving survival in chronic heart failure patients.
  • The antiarrhythmic properties of n-3 PUFA likely contribute to observed clinical benefits.
  • Further research into n-3 PUFA's role in HF pathophysiology is warranted.

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.